Navigation Links
Bionovo Announces 2011 Highlights and Year-End Financial Results
Date:3/30/2012

trogen-based hormone therapy.
  • The Company successfully completed non-clinical toxicology studies of Menerba in two animal species.  As expected, no serious adverse events or toxicities were observed to date from these studies, which were performed at doses much higher than are being tested in the Phase 3 clinical trial. The drug was well tolerated by the animals.
  • The Company has completed the manufacture of the requisite ten batches for the Phase 3 clinical trial of Menerba, and demonstrated to the FDA excellent consistency and quality.
  • The Company was active in developing and accessing the capital markets for needed funding:
  • On March 12, 2012, the Company entered into a securities purchase agreement with certain investors pursuant to which the Investors purchased an aggregate of 14,231,696 shares of its common stock and warrants to purchase 11,485,844 shares of its common stock.  The exercise price of the warrants is $0.03 per share. The warrants expire on March 30, 2012 and as of March 29, 2012, no warrants were exercised.  
  • On December 30, 2011, the Company entered into a $5 million securities purchase agreement with Socius CG II, Ltd. ("Socius").  On January 6, 2012, the Company presented Socius with a notice to purchase 105 shares of Preferred Stock for $1,050,000.  Upon receipt of the notice, Socius exercised its additional investment right for 4,468,085 common shares for $0.235 per share.  The portion of a warrant representing 35% of the Preferred Stock amount became vested and exercisable and accordingly Socius exercised the vested portion of the warrant for 1,563,830 shares for $0.235 per share.  Socius paid for the shares issued in the form of a secured promissory note.  On February 24, 2012, the Company issued Socius 105 shares of Preferred Stock and immediately thereafter redeemed all 105 shares of the Preferred Stock by offsetting the full redemption price for t
    '/>"/>

  • SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
    2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
    3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
    4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
    5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
    6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
    7. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
    8. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
    9. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
    10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
    11. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
    (Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
    (Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
    Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
    (Date:7/30/2015)... ... 30, 2015 , ... Between 2012 and 2014 HIV infection rates rose from ... on June 17th. Those untreated heroin use disorders share their needles and spread the ... needles throughout the community. Ultimately Florida’s HIV infection rates have bolstered to 23 percent ...
    (Date:7/30/2015)... Dana Point, CA (PRWEB) , ... July 30, 2015 , ... ... the highest honors available, including the very rare “no recommendations.” No recommendations means CARF ... full compliance; this is a notation that less than 3% of all facilities receive. ...
    (Date:7/30/2015)... Alexandria, VA (PRWEB) , ... July 30, 2015 ... ... applauds Drug Enforcement Administration (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution ... been scheduled for Saturday, September 26, 2015 from 10:00 AM to 2:00 PM ...
    (Date:7/30/2015)... ... July 30, 2015 , ... The Tisch ... Institute Designation , The Tisch Cancer Institute (TCI) at the Icahn School of ... center. TCI joins an elite group of 69 cancer institutions nationwide that have ...
    (Date:7/30/2015)... PA (PRWEB) , ... July 30, 2015 , ... ... inventor from Texas, has designed a personal-care device that makes it easy to apply ... Buddy” could eliminate the need for assistance when applying lotion or medication to the ...
    Breaking Medicine News(10 mins):Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
    ... The following is a,statement in response to Patrick Swayze ... CEO of the Pancreatic Cancer,Action Network, the only national ... support, community outreach and,advocacy for a cure., "We ... with,pancreatic cancer and our thoughts go out to him ...
    ... WASHINGTON and NEWARK, N.J., March 5 Besler,& ... principal, Philip,Besler, have agreed to pay the United ... fraud against the federal Medicare program, the,Justice Department ... the North Brunswick,N.J.-headquartered company counseled hospital clients to ...
    ... MINNEAPOLIS, March 5 As two of the ... implementation of the Freedom,to Breathe Act, we are ... denounced so-called "theatrical performances" in bars as a,violation ... Freedom to Breathe Act was passed to protect ...
    ... could use,a little pampering now and then. Think your mom ... Breast Cancer Coalition,(PBCC) and Doneckers of Ephrata take care of ... in 250 words or less why your mom, as a,breast ... and you and your mom could be in for a ...
    ... says , , WEDNESDAY, March 5 (HealthDay News) -- Variations ... warfarin are important in determining the initial doses of ... is being put to medical use. Last August, the ... say that doctors should consider a genetic test when ...
    ... Spheris, a leading global,provider of clinical documentation technology and ... results for the fourth quarter,ended December 31, 2007., ... fourth quarter of,2007 after the close of market trading ... call on Thursday, March 27, 2008, at 8:00 a.m. ...
    Cached Medicine News:Health News:Patrick Swayze's Diagnosis With Pancreatic Cancer: a Statement From the Pancreatic Cancer Action Network 2Health News:New Jersey Healthcare Consulting Firm to Pay U.S. $2.875 Million to Resolve Allegations of Medicare Fraud 2Health News:Leading Health Groups Strongly Support the Minnesota Department of Health's Efforts to Enforce Freedom to Breathe Act 2Health News:The Pennsylvania Breast Cancer Coalition Announces Last Chance to Enter 'Makeover for Mom' Contest 2Health News:Genetic Test Predicts Response to Warfarin 2Health News:Genetic Test Predicts Response to Warfarin 3
    Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
    Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
    The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
    The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
    Medicine Products: